HCM
CRMD icon

Highbridge Capital Management’s CorMedix CRMD Stock Holding History

Highbridge Capital Management’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,273
Closed -$44K – 1571
2015
Q2 		$44K Buy
+2,273
New +$78K ﹤0.01% 1360

Other funds holding CRMD

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Highbridge Capital Management's CRMD Position: Q3 2015 in Review

Highbridge Capital Management sold out of CorMedix (CRMD) in Q3 2015, closing a stake of 2,273 shares — an estimated $44K sold.

Highbridge Capital Management first reported a position in CRMD in Q2 2015 and held it in 1 quarter. The position peaked at $44K in Q2 2015. 54 funds tracked by Wall St. Rank hold CRMD as of Q3 2015.

  • Highbridge Capital Management reported no remaining CorMedix position as of Q3 2015 after selling out during the quarter.
  • Highbridge Capital Management sold 2,273 CorMedix shares in Q3 2015, an estimated $44K.
  • Highbridge Capital Management first reported a position in CorMedix in Q2 2015 and held it in 1 quarter.
  • Highbridge Capital Management's CorMedix position peaked at $44K in Q2 2015.
  • 54 funds tracked by Wall St. Rank held CorMedix as of Q3 2015.

Based on Highbridge Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.